Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study

Neumair P.; Joos L.; Warschkow R.; Dutly A.; Ess S.; Hitz F.; Fruh M.; Brutsche M.; Baty F.; Krahenbuhl S.; Cerny T.; Joerger M.

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study

【24h】

Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study

机译：Erlotinib对预处理的非小细胞肺癌（NSCLC）进行预处理患者的化疗具有相当的临床疗效：倾向调整的结果研究 - 基于研究的研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objectives: Controversy exists about the integration of erlotinib in patients with EGFR wildtype, advanced NSCLC.

机译：目的：存在关于Emfr Wildtype，Advanced NSCLC患者Erlotinib的争议。

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2016年第null期|共7页
作者
Neumair P.; Joos L.; Warschkow R.; Dutly A.; Ess S.; Hitz F.; Fruh M.; Brutsche M.; Baty F.; Krahenbuhl S.; Cerny T.; Joerger M.;
展开▼
作者单位

Cantonal Hosp Dept Internal Med St Gallen Switzerland;

Cantonal Hosp Dept Internal Med St Gallen Switzerland;

Cantonal Hosp Dept Surg St Gallen Switzerland;

Cantonal Hosp Dept Thorac Surg St Gallen Switzerland;

Canc Registry St Gallen Appenzell St Gallen Switzerland;

Cantonal Hosp Dept Med Oncol St Gallen Switzerland;

Cantonal Hosp Dept Med Oncol St Gallen Switzerland;

Cantonal Hosp Dept Pneumol St Gallen Switzerland;

Cantonal Hosp Dept Pneumol St Gallen Switzerland;

Univ Hosp Dept Clin Pharmacol &

Toxicol Basel Switzerland;

Cantonal Hosp Dept Med Oncol St Gallen Switzerland;

Cantonal Hosp Dept Med Oncol St Gallen Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Erlotinib; Non-small-cell lung cancer; Chemotherapy; Cancer registry;

机译：erlotinib;非小细胞肺癌;化疗;癌症登记处;

相似文献

外文文献
中文文献
专利

1. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study [J] . Neumair P., Joos L., Warschkow R., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：厄洛替尼在晚期非小细胞肺癌（NSCLC）预处理患者中具有与化疗相当的临床疗效：一项基于倾向性调整，基于结果研究的研究
2. From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. [J] . Mazzoni F, Rotella V, Pratesi N, Tumori. . 2011,第2期

机译：从临床试验到临床实践：接受化疗预处理的晚期非小细胞肺癌患者对厄洛替尼反应的预测因子。
3. Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC) [J] . TiseoM., AndreoliR., GelsominoF., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2014,第2期

机译：晚期非小细胞肺癌（NSCLC）患者的厄洛替尼药代动力学，皮肤毒性与临床结局之间的相关性
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Pre-Treatment Radiomics Models for Clinical Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC) [D] . Shaffer, Nathan Allen. 2021

机译：早期非小细胞肺癌临床结果的预处理辐射瘤模型（NSCLC）
6. Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study [O] . Seigo Minami, Takashi Kijima, Ryo Takahashi, 2012

机译：化疗联合间断性厄洛替尼和培美曲塞治疗晚期非小细胞肺癌的预治疗患者：I期剂量研究
7. PCN13 REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY [O] . Vergnenegre A., Heigener D.F., Bischoff H.G., 2011

机译：PCN13晚期或转移性非小细胞肺癌（NSCLC）第二代患者的真实生活结果：法国和德国的一项初步研究，分析了厄洛替尼与化疗的关系

Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study

摘要

著录项

相似文献

相关主题

期刊订阅